Myeloma Paper of the Day, October 1st, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Study of newly diagnosed individuals with MGUS or SMM (115 MGUS, 131 SMM) finds that 19% reported anxiety, with coping responses including religious coping, denial, frustration, irritability, and seeking social support.”

Source: Robert Orlowski/X

Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Authors: Tanvi H. Patel, Ramya Bachu, Trilok Shrivastava, Jawad Alrawabdeh, Marah Alzubi, Jael Hastings, Harold Dean, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Guido Tricot, Fenghuang Zhan, John D Shaughnessy, Frits van Rhee, Samer Al Hadidi.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.